77热门这里精品无码_91精品国产制服啪啪无码_亚洲 欧美 国产 动漫 综合_三级片日本免费亚洲

159-2642-3062 027-65317797
服務(wù)熱線（工作日：9:00-17:30）

瀏覽量: 100

  • 產(chǎn)品名稱： Research Grade Ramucirumab ( 雷莫蘆單抗 )
  • 產(chǎn)品貨號： CSD00194
  • 貨期： 現(xiàn)貨
  • 價格與訂購： 2480
  • 數(shù)量：
    庫存： 100
  • 規(guī)格： 100μg
  • 產(chǎn)品信息
  • 如何訂購
    貨號（Catalog No.）
    CSD00194
    純度(Purity)
    >95%
    濃度( Concentration)
    1mg/ml
    Formulation
    PBS buffer PH7.5
    Source
    CHO cells
    內(nèi)毒素(Endotoxin level)
    Please contact with the lab for this information.
    產(chǎn)品描述(Description)
    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
    別名(Alternative names)
    1121B,IMC-1121B,LY3009806
    靶點;物種(Specificity target name;species)
    KDR/CD309[Homo sapiens]
    活性研究（體外/體內(nèi)研究）(Activity in vitro)
    3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 (VEGFR2 Kinase Inhibitor I) is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 (VEGFR2 Kinase Inhibitor I) shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50>100 μM).
    種類(Species)
    Homo sapiens
    受體鑒定(Receptor identification)
    IgG1-kappa
    分子量(MV)
    143600.0 Da
    CAS
    15966-93-5
    存儲條件(Storage)
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Store at +4°C short term (1-2 weeks).
    Store at -20 °C 12 months.
    Store at -80°C long term.
    Note
    For research use only .